Iron Metabolism and Inflammatory Mediators in Patients with Renal Dysfunction
Tomomi Matsuoka(Nihon University), Hiroki Kobayashi(Nihon University), Masanori Abe(Japanese Society for Dialysis Therapy)
Cited by 32
Related Papers
Annual dialysis data report for 2018, JSDT Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality
|Renal Replacement Therapy|2020|170
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
|The Lancet Diabetes & Endocrinology|2023|107
Annual dialysis data report 2018, JSDT Renal Data Registry: dialysis fluid quality, hemodialysis and hemodiafiltration, peritoneal dialysis, and diabetes
|Renal Replacement Therapy|2020|49
Association of Oral Frailty with Physical Frailty and Malnutrition in Patients on Peritoneal Dialysis
|Nutrients|2025|5
3P-0836 Biological characterization of ER129614-06, a novel, non-peptide protease-activated receptor-1 (PAR-1) antagonist
|Atherosclerosis Supplements|2003|4